GlassScriptPhysician profile
Sergio A Huerta
NPI 1649233008
$11,383.48
in general payments reported to CMS, 2019-2025
37 companies · $893 in 2025
The $893 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,227 · 2020: $1,515 · 2021: $2,039 · 2022: $2,422 · 2023: $1,099 · 2024: $1,189 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,563.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,488.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,271.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,089.72 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,043.57 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $646.36 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $637.48 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $580.02 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Pfizer INC. | $552.07 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $526.12 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $429.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $166.29 | 2019-2022 | |
| Abbott Laboratories | $132.16 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $124.91 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $120.37 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Huerta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.